A Phase 3 interventional study of dronedarone (SR33589) and placebo in Atrial Fibrillation and Atrial Flutter, sponsored by Sanofi. Completed at 37 sites in 37 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2010-01-12.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.
Among the 26 studies testing dronedarone in Atrial Fibrillation, this one has the largest enrollment, is the only one that started in 2005, is one of 7 in phase 3, and was the 1st registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:
Shanghai East Hospital · Sites in China
Ages 18–80
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 11
First in 2001; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,628 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 164 across the 26 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
23 studies in Atrial Fibrillation by Sanofi: none open now, none under way, none of them phase 3. Of 23 finished, 7 (30%) have results posted.
Among the 23 studies in Atrial Fibrillation by Sanofi, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2005, is one of 11 in phase 3, and was the 2nd registered.
Sanofi’s Atrial Fibrillation studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing dronedarone in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 23 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
To assess that dronedarone is well tolerated in this population.
This is a prospective, multinational, double-blind, randomized, multi-center, placebo-controlled, parallel-group trial evaluating the effects of dronedarone versus placebo (ratio 1:1) over a minimum treatment duration of 12 months and a mean follow-up duration of 1.75 years (in AF/AFL patients). Patients can be included in the study while in atrial fibrillation/flutter or in sinus rhythm if conversion has occurred either spontaneously or following a procedure such as electrical cardioversion (or overdrive pacing) or administration of an antiarrhythmic drug.After randomization all patients will be followed until the common study end date; the last patient included in the study will be followed for 1 year. Visits will be at baseline, after 7 days, after 14 days, after one month, after three months and then every three months until end of the study. At each visit patients will be asked for the occurrence of hospitalizations or other events since the last visit. The study will be monitored by an independent Data Monitoring Committee (DMC) for safety, tolerability and efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Patients aged 75 years or older (70 years before protocol amendment 1), or patients aged at least 70 years (any age before protocol amendment 1) with one or more of the following risk factors at baseline:
Exclusion Criteria:
General criteria:
Criteria Related to a cardiac condition:
Criteria Related to Concomitant Medications:
Criteria Related to Laboratory Abnormalities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dronedarone 400mg tablets twice daily (bid)
Drug: dronedarone (SR33589)
matching placebo tablets
Drug: placebo
oral administration (tablets)
Also known as: Multaq®
oral administration (tablets)
First Hospitalization for Cardiovascular Reason or Death From Any Cause
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years
Death From Any Cause
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years
First Hospitalization for Cardiovascular Reason
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years
Cardiovascular Death
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years
Adjudicated Cardiovascular Death
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum follow-up duration: 1 year ; maximum: 2.5 years
Enrollment of patients started on June 29, 2005 and was completed on December 30, 2006. The study was conducted at 551 centers in 37 countries. The common study end date ensuring a minimum planned follow-up of one year was December 30th, 2007.
| Milestone | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| Started | 2301 | 2327 |
| Completed | 1605 | 1611 |
| Not completed | 696 | 716 |
| Withdrew: Adverse event | 293 | 191 |
| Withdrew: Protocol violation | 14 | 14 |
| Withdrew: Withdrawal by subject | 173 | 175 |
| Withdrew: Atrial fibrillation/flutter recurrence | 110 | 167 |
| Withdrew: Prohibited antiarrhythmic medication | 39 | 88 |
| Withdrew: Other prohibited medication | 5 | 3 |
| Withdrew: Family request | 6 | 8 |
| Withdrew: Not pre-specified/not coded | 56 | 70 |
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| First Hospitalization for Cardiovascular Reason or Death From Any Cause | 734 | 917 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| Death From Any Cause | 116 | 139 |
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| First Hospitalization for Cardiovascular Reason | 675 | 859 |
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| Cardiovascular Death | 65 | 94 |
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| Adjudicated Cardiovascular Death | 63 | 90 |
Collected over In both treatment groups, the median duration of exposure was about 18 months, with a maximum of 30 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dronedarone 400mg Bid | — | 456/2,291 (19.9%) | 1,584/2,291 (69.1%) |
| Placebo | — | 489/2,313 (21.1%) | 1,527/2,313 (66%) |
| Event | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 32/2291 | 45/2313 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 15/2291 | 21/2313 |
| FallInjury, poisoning and procedural complications | 20/2291 | 20/2313 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 13/2291 | 19/2313 |
| Renal failure acuteRenal and urinary disorders | 14/2291 | 4/2313 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/2291 | 11/2313 |
| Urinary tract infectionInfections and infestations | 6/2291 | 10/2313 |
| DehydrationMetabolism and nutrition disorders | 4/2291 | 10/2313 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 8/2291 | 10/2313 |
| HaematuriaRenal and urinary disorders | 7/2291 | 7/2313 |
| Event | Dronedarone 400mg Bid | Placebo |
|---|---|---|
| Any Gastrointestinal disordersGastrointestinal disorders | 573/2291 | 478/2313 |
| Any infections and infestationsInfections and infestations | 508/2291 | 533/2313 |
| Any general disorders and administration site conditionsGeneral disorders | 397/2291 | 348/2313 |
| Any musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 364/2291 | 376/2313 |
| Any nervous system disordersNervous system disorders | 362/2291 | 365/2313 |
| Any respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 315/2291 | 318/2313 |
| Any investigation disordersInvestigations | 298/2291 | 199/2313 |
| Any cardiac disordersCardiac disorders | 251/2291 | 213/2313 |
| Any skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 235/2291 | 174/2313 |
| DiarrhoeaGastrointestinal disorders | 222/2291 | 142/2313 |
| Age, Customized(participants) | Dronedarone 400mg Bid | Placebo | Total |
|---|---|---|---|
| 18 to < 65 years | 431 | 442 | 873 |
| 65 to < 75 years | 923 | 907 | 1830 |
| >= 75 years | 947 | 978 | 1925 |
| Age Continuous(years) | Dronedarone 400mg Bid | Placebo | Total |
|---|---|---|---|
| Mean | 71.6 ± 8.9 | 71.7 ± 9.0 | 71.6 ± 9.0 |
| Sex: Female, Male(Participants) | Dronedarone 400mg Bid | Placebo | Total |
|---|---|---|---|
| Female | 1131 | 1038 | 2169 |
| Male | 1170 | 1289 | 2459 |
The record gives a start of Jun 2005, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronedarone